References
- O’Brien J, Taylor JP, Ballard C, et al. Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2020;91(5):512–519. doi:10.1136/jnnp-2019-322702.
- Weil RS, Schrag AE, Warren JD, Crutch SJ, Lees AJ, Morris HR. Visual dysfunction in Parkinson’s disease. Brain. 2016;139(11):2827–2843. doi:10.1093/brain/aww175.
- Guo L, Normando EM, Shah PA, De Groef L, Cordeiro MF. Oculo-visual abnormalities in Parkinson’s disease: possible value as biomarkers. Mov Disord. 2018;33(9):1390–1406. doi:10.1002/mds.27454.
- Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology. 1992;42(4):887–890. doi:10.1212/wnl.42.4.887.
- Büttner T, Kuhn W, Müller T, Patzold T, Heidbrink K, Przuntek H. Distorted color discrimination in ‘de novo’ parkinsonian patients. Neurology. 1995;45(2):386–387. doi:10.1212/wnl.45.2.386.
- Cortical visual screening test. 2020. The Corvist. [ ONLINE] https://corvist.org. [Accessed October 3, 2020.]
- Schadlu AP, Schadlu R, Shepherd JB 3rd. Charles Bonnet syndrome: a review. Curr Opin Ophthalmol. 2009 May;20(3):219–222. doi:10.1097/ICU.0b013e328329b643.
- Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci. 1998;1(8):738–742. doi:10.1038/3738.
- Silva MF, Faria P, Regateiro FS, et al. Independent patterns of damage within magno-, parvo- and koniocellular pathways in Parkinson’s disease. Brain. 2005;128(Pt 10):2260–2271. doi:10.1093/brain/awh581.
- Lee JY, Kim JM, Ahn J, Kim HJ, Jeon BS, Kim TW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s disease. Mov Disord. 2014;29(1):61–67. doi:10.1002/mds.25543.
- Bodis-Wollner I, Kozlowski PB, Glazman S, Miri S. α-synuclein in the inner retina in Parkinson’s disease. Ann Neurol. 2014;75(6):964–966. doi:10.1002/ana.24182.
- Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson’s disease patients. Trends Neurosci. 1990;13(7):296–302. doi:10.1016/0166-2236(90)90113-o.
- Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1998;21:289–295.
- Osa AA, Bowen TJ, Whitson JT. Charles bonnet syndrome in a patient with Parkinson’s disease and bilateral posterior capsule opacification. Int Med Case Rep J. 2020;13:7–10. doi:10.2147/IMCRJ.S218687.